Edgewell Personal Care (EPC) PT Lowered to $88 at RBC Capital Following 4Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Barclays Downgrades Edgewell Personal Care (EPC) to Underweight, FY 2018 At Risk
November 10, 2017 6:54 AM ESTBarclays downgraded Edgewell Personal Care (NYSE: EPC) from Equalweight to Underweight with a price target of $55.00 (from $75.00).
Analyst Lauren Lieberman expects competitive pressure to intensify in 2018 and sees knock-on impacts to FY guidance along with potential for continued top-line misses which... More
Pre-Open Movers 11/09: (OTIC) (SAGE) (ROKU) Higher; (VSTO) (OPK) (EPC) Lower (more...)
November 9, 2017 9:23 AM ESTToday's Pre-Open Movers
Otonomy, Inc. (NASDAQ: OTIC) 108.8% HIGHER; announced that the AVERTS-2 Phase 3 clinical trial of OTIVIDEX in patients with Meniere's disease achieved its primary efficacy endpoint (p value = 0.029). Otonomy plans to review these results with the U.S. Food and Drug Administration (FDA) and discuss clinical requirements for registration of OTIVIDEX for patients with Meniere's disease.
Sage Therapeutics (NASDAQ:... More
Edgewell Personal Care Company (EPC) Misses Q4 EPS by 3c, Miss on Revenues; Offers FY18 EPS Guidace Below Consensus
November 9, 2017 6:08 AM ESTEdgewell Personal Care Company (NYSE: EPC) reported Q4 EPS of $1.00, $0.03 worse than the analyst estimate of $1.03. Revenue for the quarter came in at $564.9 million versus the consensus estimate of $588.28 million.
Executive Summary
Net sales on a reported basis were $564.9 million in the fourth quarter of fiscal 2017, a decrease of 7.5% when compared to the prior year quarter, and $2,298.4 million for the full year, a decrease of 2.7% compared to the prior year. Organic net sales were down 8.4% for the quarter and 2.8% for the full year. (Organic net sales exclude sales growth from the Bulldog... More